Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1147-1149
doi: 10.1161/01.ATV.0000134296.22448.eb
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sata, M.
Right arrow Articles by Nagai, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sata, M.
Right arrow Articles by Nagai, R.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1147.)
© 2004 American Heart Association, Inc.


Editorials

Origin of Neointimal Cells in Autologous Vein Graft

Masataka Sata; Ryozo Nagai

From the Department of Cardiovascular Medicine, University of Tokyo, Graduate School of Medicine, Tokyo, Japan.

Correspondence to Dr Masataka Sata, Department of Cardiovascular Medicine, University of Tokyo, Graduate School of Medicine, 7-3-1 Hongo Bunkyo-ku, Tokyo 113-8655 Japan. E-mail msata-circ@umin.ac.jp


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

Since the first aortocoronary vein graft implantation was performed in 1967,1 vascular bypass surgery using saphenous vein grafts has become an established therapeutic procedure for patients with ischemic coronary or peripheral arterial diseases. Despite increasing use of arterial grafts in coronary bypass surgery,2 autologous vein remains an important and convenient conduit for surgical revascularization.3 However, vein grafts are associated with poor long-term patencies.4 During the first year after bypass surgery, up to 15% of venous grafts occlude. Between 1 and 6 years, the graft attrition rate is 1% to 2% per year, which increases to 4% between 6 and 10 years after surgery.5 By 10 years, only 60% of vein grafts are patent and only 50% of patent vein grafts are free of significant stenosis.5

See page 1180

Graft occlusion arises either from early thrombosis or from the later onset of graft narrowing.3 After implantation, the vein graft is exposed to immediate increases in flow, shear stress, circumferential stress, radial deformation, and pulsatile stress.6 Progressive thickening of vein grafts, mainly caused by neointima formation in the inner layer, is supposed to be the adaptation of these vessels from the low-pressure venous system to the arterial circulation. Smooth muscle cell (SMC) accumulation7,8 and matrix biosynthesis by SMCs4,9 are key events in the pathogenesis of neointima formation in vein grafts. However, the molecular mechanism of SMC hyperplasia is largely unknown. Consequently, no effective therapy has been established to prevent vein graft failure.

Experimental models of venous bypass graft have been described in . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Q. Xu, M. Sata, and R. Nagai
Mouse Models of Vein Grafts
Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): e185 - e187.
[Full Text] [PDF]